The YfkO Nitroreductase from Bacillus Licheniformis on Gold-Coated Superparamagnetic Nanoparticles: Towards a Novel Directed Enzyme Prodrug Therapy Approach

The bacterial nitroreductase NfnB has been the focus of a great deal of research for its use in directed enzyme prodrug therapy in combination with the nitroreductase prodrug CB1954 with this combination of enzyme and prodrug even entering clinical trials. Despite some promising results, there are m...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2021-04, Vol.13 (4), p.517
Main Authors: Ball, Patrick, Hobbs, Robert, Anderson, Simon, Thompson, Emma, Gwenin, Vanessa, Von Ruhland, Christopher, Gwenin, Christopher
Format: Article
Language:English
Subjects:
cancer
Cancer therapies
CB1954
Chemotherapy
Chromatography
DEPT
E coli
Enzymes
Nanoparticles
nitroreductase
Ovarian cancer
prodrug
Proteins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c505t-7b16e0d8a45dfe1a92ca60def9442674222671f5c5b2152644fc9a07b1734dac3
cites cdi_FETCH-LOGICAL-c505t-7b16e0d8a45dfe1a92ca60def9442674222671f5c5b2152644fc9a07b1734dac3
container_end_page
container_issue 4
container_start_page 517
container_title Pharmaceutics
container_volume 13
creator Ball, Patrick
Hobbs, Robert
Anderson, Simon
Thompson, Emma
Gwenin, Vanessa
Von Ruhland, Christopher
Gwenin, Christopher
description The bacterial nitroreductase NfnB has been the focus of a great deal of research for its use in directed enzyme prodrug therapy in combination with the nitroreductase prodrug CB1954 with this combination of enzyme and prodrug even entering clinical trials. Despite some promising results, there are major limitations to this research, such as the fact that the lowest reported Km for this enzyme far exceeds the maximum dosage of CB1954. Due to these limitations, new enzymes are now being investigated for their potential use in directed enzyme prodrug therapy. One such enzyme that has proved promising is the YfkO nitroreductase from Bacillus Licheniformis. Upon investigation, the YfkO nitroreductase was shown to have a much lower Km (below the maximum dosage) than that of NfnB as well as the fact that when reacting with the prodrug it produces a much more favourable ratio of enzymatic products than NfnB, forming more of the desired 4-hydroxylamine derivative of CB1954.
doi_str_mv 10.3390/pharmaceutics13040517
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_24a62a4fe0ae4f908ea6f8377f2c0041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_24a62a4fe0ae4f908ea6f8377f2c0041</doaj_id><sourcerecordid>2520873357</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-7b16e0d8a45dfe1a92ca60def9442674222671f5c5b2152644fc9a07b1734dac3</originalsourceid><addsrcrecordid>eNptkk1vEzEQhlcIRKvSnwCyxIVLwJ_7wQGphLZUilIkwoGTNbHHyYbd9dbeLUp_Cz8Wh4SqRfhgj8bv-2hmNFn2ktG3QlT0Xb-G0ILBcahNZIJKqljxJDtmVVVNZMXF0wfxUXYa44amIwQrRfU8O0oQViqRH2e_Fmsk392PazKvh-AD2tEMEJG44FvyEUzdNGMks9qssaudD20die_IpW_sZOphQEu-jj2GHgK0sOowlUTm0PmUSGGD8T1Z-J8QbCRA5v4WG_KpDmh2zvPubtsi-RK8DeOKpFoC9Fty1vfBg1m_yJ45aCKeHt6T7NvF-WL6eTK7vryans0mRlE1TIoly5HaEqSyDhlU3EBOLbpKSp4XkvN0M6eMWnKmeC6lMxXQZCuEtGDESXa151oPG92HuoWw1R5q_Sfhw0ofmtFcQs5BOqSA0lW0RMhdKYrCcUOpZIn1Yc_qx2WL1mA3BGgeQR__dPVar_ytLmlBmZQJ8OYACP5mxDjoNHKDTQMd-jFqrjgtCyFUkaSv_5Fu_Bi6NKqkEokmONsB1V5lgo8xoLsvhlG9Wyf933VKvlcPO7l3_V0e8Rt2l8zm</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2530143214</pqid></control><display><type>article</type><title>The YfkO Nitroreductase from Bacillus Licheniformis on Gold-Coated Superparamagnetic Nanoparticles: Towards a Novel Directed Enzyme Prodrug Therapy Approach</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Ball, Patrick ; Hobbs, Robert ; Anderson, Simon ; Thompson, Emma ; Gwenin, Vanessa ; Von Ruhland, Christopher ; Gwenin, Christopher</creator><creatorcontrib>Ball, Patrick ; Hobbs, Robert ; Anderson, Simon ; Thompson, Emma ; Gwenin, Vanessa ; Von Ruhland, Christopher ; Gwenin, Christopher</creatorcontrib><description>The bacterial nitroreductase NfnB has been the focus of a great deal of research for its use in directed enzyme prodrug therapy in combination with the nitroreductase prodrug CB1954 with this combination of enzyme and prodrug even entering clinical trials. Despite some promising results, there are major limitations to this research, such as the fact that the lowest reported Km for this enzyme far exceeds the maximum dosage of CB1954. Due to these limitations, new enzymes are now being investigated for their potential use in directed enzyme prodrug therapy. One such enzyme that has proved promising is the YfkO nitroreductase from Bacillus Licheniformis. Upon investigation, the YfkO nitroreductase was shown to have a much lower Km (below the maximum dosage) than that of NfnB as well as the fact that when reacting with the prodrug it produces a much more favourable ratio of enzymatic products than NfnB, forming more of the desired 4-hydroxylamine derivative of CB1954.</description><identifier>ISSN: 1999-4923</identifier><identifier>EISSN: 1999-4923</identifier><identifier>DOI: 10.3390/pharmaceutics13040517</identifier><identifier>PMID: 33918536</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>cancer ; Cancer therapies ; CB1954 ; Chemotherapy ; Chromatography ; DEPT ; E coli ; Enzymes ; Nanoparticles ; nitroreductase ; Ovarian cancer ; prodrug ; Proteins</subject><ispartof>Pharmaceutics, 2021-04, Vol.13 (4), p.517</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-7b16e0d8a45dfe1a92ca60def9442674222671f5c5b2152644fc9a07b1734dac3</citedby><cites>FETCH-LOGICAL-c505t-7b16e0d8a45dfe1a92ca60def9442674222671f5c5b2152644fc9a07b1734dac3</cites><orcidid>0000-0001-7147-2652 ; 0000-0003-0363-8168</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2530143214/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2530143214?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33918536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ball, Patrick</creatorcontrib><creatorcontrib>Hobbs, Robert</creatorcontrib><creatorcontrib>Anderson, Simon</creatorcontrib><creatorcontrib>Thompson, Emma</creatorcontrib><creatorcontrib>Gwenin, Vanessa</creatorcontrib><creatorcontrib>Von Ruhland, Christopher</creatorcontrib><creatorcontrib>Gwenin, Christopher</creatorcontrib><title>The YfkO Nitroreductase from Bacillus Licheniformis on Gold-Coated Superparamagnetic Nanoparticles: Towards a Novel Directed Enzyme Prodrug Therapy Approach</title><title>Pharmaceutics</title><addtitle>Pharmaceutics</addtitle><description>The bacterial nitroreductase NfnB has been the focus of a great deal of research for its use in directed enzyme prodrug therapy in combination with the nitroreductase prodrug CB1954 with this combination of enzyme and prodrug even entering clinical trials. Despite some promising results, there are major limitations to this research, such as the fact that the lowest reported Km for this enzyme far exceeds the maximum dosage of CB1954. Due to these limitations, new enzymes are now being investigated for their potential use in directed enzyme prodrug therapy. One such enzyme that has proved promising is the YfkO nitroreductase from Bacillus Licheniformis. Upon investigation, the YfkO nitroreductase was shown to have a much lower Km (below the maximum dosage) than that of NfnB as well as the fact that when reacting with the prodrug it produces a much more favourable ratio of enzymatic products than NfnB, forming more of the desired 4-hydroxylamine derivative of CB1954.</description><subject>cancer</subject><subject>Cancer therapies</subject><subject>CB1954</subject><subject>Chemotherapy</subject><subject>Chromatography</subject><subject>DEPT</subject><subject>E coli</subject><subject>Enzymes</subject><subject>Nanoparticles</subject><subject>nitroreductase</subject><subject>Ovarian cancer</subject><subject>prodrug</subject><subject>Proteins</subject><issn>1999-4923</issn><issn>1999-4923</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1vEzEQhlcIRKvSnwCyxIVLwJ_7wQGphLZUilIkwoGTNbHHyYbd9dbeLUp_Cz8Wh4SqRfhgj8bv-2hmNFn2ktG3QlT0Xb-G0ILBcahNZIJKqljxJDtmVVVNZMXF0wfxUXYa44amIwQrRfU8O0oQViqRH2e_Fmsk392PazKvh-AD2tEMEJG44FvyEUzdNGMks9qssaudD20die_IpW_sZOphQEu-jj2GHgK0sOowlUTm0PmUSGGD8T1Z-J8QbCRA5v4WG_KpDmh2zvPubtsi-RK8DeOKpFoC9Fty1vfBg1m_yJ45aCKeHt6T7NvF-WL6eTK7vryans0mRlE1TIoly5HaEqSyDhlU3EBOLbpKSp4XkvN0M6eMWnKmeC6lMxXQZCuEtGDESXa151oPG92HuoWw1R5q_Sfhw0ofmtFcQs5BOqSA0lW0RMhdKYrCcUOpZIn1Yc_qx2WL1mA3BGgeQR__dPVar_ytLmlBmZQJ8OYACP5mxDjoNHKDTQMd-jFqrjgtCyFUkaSv_5Fu_Bi6NKqkEokmONsB1V5lgo8xoLsvhlG9Wyf933VKvlcPO7l3_V0e8Rt2l8zm</recordid><startdate>20210409</startdate><enddate>20210409</enddate><creator>Ball, Patrick</creator><creator>Hobbs, Robert</creator><creator>Anderson, Simon</creator><creator>Thompson, Emma</creator><creator>Gwenin, Vanessa</creator><creator>Von Ruhland, Christopher</creator><creator>Gwenin, Christopher</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7147-2652</orcidid><orcidid>https://orcid.org/0000-0003-0363-8168</orcidid></search><sort><creationdate>20210409</creationdate><title>The YfkO Nitroreductase from Bacillus Licheniformis on Gold-Coated Superparamagnetic Nanoparticles: Towards a Novel Directed Enzyme Prodrug Therapy Approach</title><author>Ball, Patrick ; Hobbs, Robert ; Anderson, Simon ; Thompson, Emma ; Gwenin, Vanessa ; Von Ruhland, Christopher ; Gwenin, Christopher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-7b16e0d8a45dfe1a92ca60def9442674222671f5c5b2152644fc9a07b1734dac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>cancer</topic><topic>Cancer therapies</topic><topic>CB1954</topic><topic>Chemotherapy</topic><topic>Chromatography</topic><topic>DEPT</topic><topic>E coli</topic><topic>Enzymes</topic><topic>Nanoparticles</topic><topic>nitroreductase</topic><topic>Ovarian cancer</topic><topic>prodrug</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ball, Patrick</creatorcontrib><creatorcontrib>Hobbs, Robert</creatorcontrib><creatorcontrib>Anderson, Simon</creatorcontrib><creatorcontrib>Thompson, Emma</creatorcontrib><creatorcontrib>Gwenin, Vanessa</creatorcontrib><creatorcontrib>Von Ruhland, Christopher</creatorcontrib><creatorcontrib>Gwenin, Christopher</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ball, Patrick</au><au>Hobbs, Robert</au><au>Anderson, Simon</au><au>Thompson, Emma</au><au>Gwenin, Vanessa</au><au>Von Ruhland, Christopher</au><au>Gwenin, Christopher</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The YfkO Nitroreductase from Bacillus Licheniformis on Gold-Coated Superparamagnetic Nanoparticles: Towards a Novel Directed Enzyme Prodrug Therapy Approach</atitle><jtitle>Pharmaceutics</jtitle><addtitle>Pharmaceutics</addtitle><date>2021-04-09</date><risdate>2021</risdate><volume>13</volume><issue>4</issue><spage>517</spage><pages>517-</pages><issn>1999-4923</issn><eissn>1999-4923</eissn><abstract>The bacterial nitroreductase NfnB has been the focus of a great deal of research for its use in directed enzyme prodrug therapy in combination with the nitroreductase prodrug CB1954 with this combination of enzyme and prodrug even entering clinical trials. Despite some promising results, there are major limitations to this research, such as the fact that the lowest reported Km for this enzyme far exceeds the maximum dosage of CB1954. Due to these limitations, new enzymes are now being investigated for their potential use in directed enzyme prodrug therapy. One such enzyme that has proved promising is the YfkO nitroreductase from Bacillus Licheniformis. Upon investigation, the YfkO nitroreductase was shown to have a much lower Km (below the maximum dosage) than that of NfnB as well as the fact that when reacting with the prodrug it produces a much more favourable ratio of enzymatic products than NfnB, forming more of the desired 4-hydroxylamine derivative of CB1954.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33918536</pmid><doi>10.3390/pharmaceutics13040517</doi><orcidid>https://orcid.org/0000-0001-7147-2652</orcidid><orcidid>https://orcid.org/0000-0003-0363-8168</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1999-4923
ispartof Pharmaceutics, 2021-04, Vol.13 (4), p.517
issn 1999-4923
1999-4923
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_24a62a4fe0ae4f908ea6f8377f2c0041
source Publicly Available Content Database; PubMed Central
subjects cancer
Cancer therapies
CB1954
Chemotherapy
Chromatography
DEPT
E coli
Enzymes
Nanoparticles
nitroreductase
Ovarian cancer
prodrug
Proteins
title The YfkO Nitroreductase from Bacillus Licheniformis on Gold-Coated Superparamagnetic Nanoparticles: Towards a Novel Directed Enzyme Prodrug Therapy Approach
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A17%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20YfkO%20Nitroreductase%20from%20Bacillus%20Licheniformis%20on%20Gold-Coated%20Superparamagnetic%20Nanoparticles:%20Towards%20a%20Novel%20Directed%20Enzyme%20Prodrug%20Therapy%20Approach&rft.jtitle=Pharmaceutics&rft.au=Ball,%20Patrick&rft.date=2021-04-09&rft.volume=13&rft.issue=4&rft.spage=517&rft.pages=517-&rft.issn=1999-4923&rft.eissn=1999-4923&rft_id=info:doi/10.3390/pharmaceutics13040517&rft_dat=%3Cproquest_doaj_%3E2520873357%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c505t-7b16e0d8a45dfe1a92ca60def9442674222671f5c5b2152644fc9a07b1734dac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2530143214&rft_id=info:pmid/33918536&rfr_iscdi=true